Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 1.02 (Termination of a Material Definitive Agreement). Mass cytometry business sale shifted from Multiplex Bio to Element Biosystems, following a superior proposal from GMT Venture.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Mass cytometry business sale shifted from Multiplex Bio to Element Biosystems, following a superior proposal from GMT Venture
- Element purchase price: $5.5 million cash, cash-free and debt-free, subject to customary adjustments
- Company owes Multiplex Bio a $1.5 million termination fee, with GMT Venture contributing $1.0 million
- Closing requires stockholder approval, completion of the Treeline merger and other customary conditions
- Potential downside: $1.0 million Element termination fee plus up to $250,000 expense reimbursement if the transaction fails under specified conditions
Item 1.02 · Termination of a Material Definitive Agreement
- Item 1.02 references Item 1.01 for termination details of the Multiplex Bio Purchase Agreement
- Agreement terms remain governed by the July 28, 2026 filing and July 29, 2026 amendment
- Investors should review Item 1.01 and Exhibit 2.1 for the termination’s financial and strategic implications
Item 7.01 · Regulation FD Disclosure
- September 30, 2026 press release announces proposed Business sale and Treeline merger transactions
- Both transactions require stockholder approvals, creating execution and timing risk
- Potential outcomes include termination fees, competing bids, litigation costs and unexpected liabilities
- Proposed transactions could affect Nasdaq listing, employee retention, customer relationships and management focus
Item EX-99.1 · Exhibit EX-99.1
- Multiplex Bio sale terminated; Mass Cytometry business sold to GMT Venture’s Element Biosystems for $5.5 million cash
- Avoiding Multiplex’s required $10 million working-capital loan improves Treeline merger exchange-ratio net cash by approximately $15 million
- Element transaction and Treeline merger both expected to close by end of 2026, subject to stockholder approval and customary conditions
- Sale transfers CyTOF, Hyperion, and Maxpar platforms while preserving customer and team continuity under new ownership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.